LONDON--(BUSINESS WIRE)--GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an ...
Previously, the treatment had only been available as a lyophilized powder for reconstitution that required administration by a healthcare professional. The Food and Drug Administration has approved ...
GlaxoSmithKline’s Nucala has suffered against a more convenient AstraZeneca rival, but the company finally has an answer. Thursday, the FDA greenlighted two new delivery options for Nucala: an ...
The US Food and Drug Administration (FDA) has approved two new methods for administering mepolizumab (Nucala, GlaxoSmithKline), an autoinjector and a prefilled safety syringe, which patients or ...
In its heated severe asthma fight with AstraZeneca’s Fasenra, GlaxoSmithKline could take solace in the fact that its drug was more convenient for patients, with a self-administered injection option.
The product is available in 100mg single-dose vials for reconstitution and in 100mg/mL single-dose prefilled autoinjectors and glass syringes. The Food and Drug Administration (FDA) has approved ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I being given NUCALA? NUCALA contains the active ingredient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback